Prototype Drug Unit 3 & 4- Sumatriptan

Question 1

Therapeutic classification

Answer 1

Antimigraine agent

Question 2

Pharmacologic classification

Answer 2

Serotonin receptor agonist

Question 3

Therapeutic effects and uses

Answer 3

It is used to relieve acute migraine headaches.

Question 4

Mechanism of action

Answer 4

Sumatriptan activates the 5-HT1 serotonin receptors on intracranial and extracerebral blood vessels.

Question 5

Route

Answer 5

PO, intranasal, subcutaneous

Question 6

Absorption

Answer 6

15% PO; 97% subcutaneous

Question 7

Distribution

Answer 7

Widely distributed; crosses the placenta; secreted in breast milk; less than 21% bound to plasma protein

Question 8

Primary metabolism

Answer 8

Hepatic

Question 9

Primary excretion

Answer 9

60% renal; 40% feces

Question 10

Adverse effects

Answer 10

mild and transient dizziness or nausea, diarrhea, mylagia, and inflammation and pain at the subcutaneous injection site.

Question 11

Contraindication/Precautions

Answer 11

Contraindication: coronary artery disease, cerebrovascular disease, or peripheral vascular disease. Uncontrolled hypertensions, hyperholesterolemia, or people who have a family history of cardiovascular disease. Serious renal or hepatic impairments. Pregnant women

Question 12

Drug interactions

Answer 12

Should not be used within 2 weeks of MAOIs or SSRIs. Should be avoided withing 24 hours of ergot alkaloids.

Question 13

Herbal/food interactions

Answer 13

St. John’s wort and feverfew should be avoided during therapy with sumatriptan

Question 14

Pregnancy Category

Answer 14

C